Week In Review: Suzhou's Adagene To Stage $125 Million IPO On NASDAQ
January 23, 2021 at 14:10 PM EST
Adagene, a Suzhou immunotherapy company, plans to raise up to $125 million in a US IPO on the NASDAQ Exchange. Suzhou Sinovent completed a pre-IPO financing of at least $30 million in a round led by Oceanpine Healthcare Fund.
